US EditionJ INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025
- On June 1, 2025, in Seoul, Korea, J INTS BIO revealed preliminary findings from their worldwide Phase 1/2 clinical study of JIN-A02, a fourth-generation EGFR-TKI, with a presentation scheduled at ASCO 2025 in Chicago.
- The trial addresses resistance mutations like C797S, which emerge after failure of third-generation EGFR-TKIs, the current first-line treatment for EGFR-mutant NSCLC.
- Key findings showed confirmed partial responses across 50mg, 100mg, and 300mg doses, with a 77.3% tumor reduction at 50mg sustained over six cycles and notable brain metastases reduction at higher doses.
- JIN-A02 exhibited no dose-limiting toxicities up to 300mg, with mostly mild adverse events common to EGFR inhibitors, supporting an excellent safety profile and prolonged patient treatment durations.
- J INTS BIO earned selection for the government’s '2025 Baby Unicorn Fostering Project', securing dual funding to accelerate Phase 2 trials and global expansion over two years alongside private investment.
Insights by Ground AI
Does this summary seem wrong?
74 Articles
74 Articles
All
Left
4
Center
23
Right
10
Coverage Details
Total News Sources74
Leaning Left4Leaning Right10Center23Last UpdatedBias Distribution62% Center
Bias Distribution
- 62% of the sources are Center
62% Center
11%
C 62%
R 27%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
